Business Context and Reporting Period
Xilio Therapeutics, Inc. (XLO) is a clinical-stage biotechnology company developing tumor-activated, or masked, immuno-oncology (I-O) therapies designed to minimize systemic toxicity. The company's proprietary platform localizes anti-tumor activity within the tumor microenvironment. This 10-K filing covers the fiscal year ended December 31, 2024. As of the filing date, the company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $6.3 million | $0 |
| Net Loss | $(58.2) million | $(76.4) million |
| Operating Expenses | $66.9 million | $79.1 million |
| Cash and Cash Equivalents (Dec 31, 2024) | $55.3 million | $44.7 million |
| Accumulated Deficit | $(383.8) million | $(325.5) million |
| Net Cash Used in Operating Activities | $(18.4) million | $(68.6) million |
Revenue Composition: The $6.3 million in revenue for 2024 was derived entirely from license revenue recognized under the agreement with Gilead Sciences, Inc. The company has no product sales revenue.
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $6.3 million in license revenue in 2024, compared to zero in 2023, driven by the Gilead license agreement executed in March 2024.
- Expense Reduction: Total operating expenses decreased by $12.2 million (15.4%) year-over-year. Research and Development (R&D) expenses declined by $10.9 million, primarily due to the discontinuation of the XTX202 program and reduced personnel costs following a March 2024 restructuring. General and Administrative (G&A) expenses decreased by $2.2 million.
- Restructuring Costs: The company incurred $0.9 million in restructuring expenses in 2024 related to a workforce reduction of 15 employees (approximately 21% of the workforce at the time).
- Debt Repayment: The company fully repaid its $10.0 million term loan with Pacific Western Bank in the first quarter of 2024, eliminating interest expense associated with this debt.
Guidance, Outlook, and Risks
Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern. Management estimates that cash on hand ($55.3 million) combined with $52.0 million in upfront payments received from AbbVie in February 2025 will fund operations only into the first quarter of 2026. Additional capital will be required to sustain operations beyond this period.
Strategic Developments:
- AbbVie Collaboration: In February 2025, Xilio entered a collaboration agreement with AbbVie for up to four programs, receiving $52.0 million in upfront payments ($42.0 million cash and $10.0 million equity investment). Potential contingent payments total approximately $2.1 billion.
- Gilead Agreement: The company continues to develop XTX301 (tumor-activated IL-12) under an exclusive license with Gilead, with a potential $75.0 million transition fee and up to $517.5 million in milestones.
- Clinical Progress: Vilastobart (XTX101) showed preliminary Phase 2 proof-of-concept data in microsatellite stable colorectal cancer (MSS CRC) in January 2025. XTX301 reported preliminary Phase 1 data in December 2024.
Key Risks:
- Liquidity: Failure to secure additional capital could force cost reductions, delays in R&D, or liquidation.
- Development Risk: All product candidates are in early clinical or preclinical stages; success is not guaranteed.
- Manufacturing Dependence: The company relies on WuXi Biologics in China for manufacturing, exposing it to geopolitical and supply chain risks.
- Regulatory: No products have received regulatory approval; the approval process is uncertain and costly.
Investor Verification Checklist
- Cash Runway: Verify the exact timing of the AbbVie upfront payment receipt and confirm the projected burn rate to validate the "first quarter 2026" liquidity estimate.
- Revenue Recognition: Review the specific accounting treatment of the Gilead license revenue to understand the deferred revenue balance ($32.8 million) and the timeline for future recognition.
- AbbVie Deal Terms: Examine the specific milestones and conditions required to unlock the $2.1 billion in contingent payments from the AbbVie agreement.
- Manufacturing Risks: Assess the impact of potential U.S. legislation (e.g., BIOSECURE Act) on the company's reliance on WuXi Biologics.
- Stock Dilution: Monitor future equity financing needs, as the company has no committed external funding sources beyond the AbbVie deal and may need to issue dilutive securities.